Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development ProgramsGlobeNewsWire • 06/18/20
Assembly Biosciences, Inc. (ASMB) Assembly Biosciences' HBV Portfolio Progress Conference Call (Transcript)Seeking Alpha • 05/13/20
Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/31/20
Assembly Biosciences (ASMB) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/04/20
Assembly Biosciences Announces the Closing of its Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesGlobeNewsWire • 12/16/19
Stock Upgrades: Assembly Biosciences Shows Rising Relative StrengthInvestors Business Daily • 12/10/19
Data for Assembly Biosciences’ First and Second Generation HBV Core Inhibitors in Development for the Treatment of Chronic Hepatitis B Highlighted in Late-Breaker Poster Session at AASLD 2019GlobeNewsWire • 11/11/19
Assembly Biosciences (ASMB) Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4)GlobeNewsWire • 11/07/19
Assembly Biosciences Reports Inducement Grant under NASDAQ Listing Rule 5635(c)(4).GlobeNewsWire • 10/28/19
This Biotech Stock Doubled In Two Days On Potential Hepatitis CureInvestors Business Daily • 10/17/19
Safety and Antiviral Activity of Assembly Biosciences’ First and Second Generation Core Inhibitor Candidates In the Treatment of Chronic Hepatitis B to be Featured in a Late Breaking Session at AASLDGlobeNewsWire • 10/16/19